Prostate cancer prevention: What do we know now, and when will we know more?

Ian M Thompson, Joseph Basler, Deborah Hensley, Dendra Von Merveldt, Carol A. Jenkins, Betsy Higgins, Robin Leach, Dean Troyer, Brad Pollock

Producción científica: Review articlerevisión exhaustiva

11 Citas (Scopus)

Resumen

Prostate cancer prevention is now one of the most aggressively investigated areas of urologic oncology, with > 30,000 men currently participating in clinical trials in the United States alone. The Prostate Cancer Prevention Trial will complete end-of-study prostate biopsies in May 2004, and the Selenium and Vitamin E Cancer Prevention Trial is rapidly reaching its accrual goal 1-2 years ahead of schedule. These 2 studies will give definitive answers regarding 3 of the most important potential preventive interventions: finasteride, vitamin E, and selenium. Many phase II and biomarker-modulation studies are also ongoing, testing a host of other interventions. It is hoped that, within a short period of time, the clinician will be provided with strategies to reduce the risk of the disease.

Idioma originalEnglish (US)
Páginas (desde-hasta)215-220
Número de páginas6
PublicaciónClinical Prostate Cancer
Volumen1
N.º4
DOI
EstadoPublished - mar 2003

ASJC Scopus subject areas

  • Oncology
  • Urology

Huella

Profundice en los temas de investigación de 'Prostate cancer prevention: What do we know now, and when will we know more?'. En conjunto forman una huella única.

Citar esto